Basic information Ocular hypotensive drug Clinical Study Adverse reactions Precautions Safety Related Supplier

ChemicalBook Product Catalog Biochemical Engineering Inhibitors Neuronal Signaling Adrenergic Receptor agonists Brimonidine Tartrate

1/1

Brimonidine Tartrate NEW

$41.00 100mg

$126.00 500mg

Min. Order
Purity99.83%
Cas No70359-46-5
Supply Ability10g
Update time2024-11-19

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

5YR

United States

show more

Chemical Properties

Product Name	Brimonidine Tartrate
CAS No	70359-46-5
EC-No
Min. Order
Purity	99.83%
Supply Ability	10g
Release date	2024/11/19

Product Introduction

Bioactivity

Name	Brimonidine Tartrate
Description	Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension.
In vitro	Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). At elevated intraocular pressure, the use of Brimonidine significantly protected retinal ganglion cells and prevented further cell loss. Brimonidine injection into the eyes of SD rats increased the number of brain-derived neurotrophic factor-positive retinal ganglion cells from 55% to 166%. Brimonidine prevented further ganglion cell loss after 10 days of elevated IOP.Brimonidine increased immunoreactivity for glial fibrillary acidic protein in the hypertensive retina of attenuated eyes.
In vivo	Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). At elevated intraocular pressure, the use of Brimonidine significantly protected retinal ganglion cells and prevented further cell loss. Brimonidine injection into the eyes of SD rats increased the number of brain-derived neurotrophic factor-positive retinal ganglion cells from 55% to 166%. Brimonidine prevented further ganglion cell loss after 10 days of elevated IOP.Brimonidine increased immunoreactivity for glial fibrillary acidic protein in the hypertensive retina of attenuated eyes.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 16.67 mg/mL (37.69 mM), Sonication is recommended. H2O : 56.53 mM
Keywords	AGN190342 \| AGN-190342 \| Brimonidine \| Adrenergic Receptor \| AGN 190342 Tartrate \| Brimonidine Tartrate \| UK 14304 \| Inhibitor \| Beta Receptor \| UK14304 \| UK 14304 Tartrate \| UK-14304 \| AGN 190342 \| AGN-190342 Tartrate \| inhibit \| 304 Tartrate \| AGN190342 Tartrate \| UK14304 Tartrate \| UK-14304 Tartrate
Inhibitors Related	Olanzapine \| Mirtazapine \| Octopamine hydrochloride \| Gemfibrozil \| Dexmedetomidine hydrochloride \| Phenylephrine hydrochloride \| Isoprenaline hydrochloride \| Amitriptyline hydrochloride \| Trazodone hydrochloride \| Mianserin hydrochloride
Related Compound Libraries	Bioactive Compound Library \| Anti-Neurodegenerative Disease Compound Library \| Membrane Protein-targeted Compound Library \| EMA Approved Drug Library \| Anti-Cancer Clinical Compound Library \| Drug Repurposing Compound Library \| Anti-Cancer Approved Drug Library \| Bioactive Compounds Library Max \| GPCR Compound Library \| Anti-Cancer Drug Library

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book